SLC16A3 and acute myeloid leukemia: To evaluate a possible correlation between MCT1 or MCT4 expression level and overall survival of AML patients, we stratified all AMLs into three risk group according to the European LeukemiaNet (ELN) risk classification (33) and classified MCT1/4 expression levels as: low (MCT1 ≤ -0.2; MCT4 ≤ -0.07); high (MCT1≥ -0.2; MCT4 ≥ -0.07).